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Deleted in liver cancer 2 (DLC2) is a candidate tumor suppressor protein found to be underexpressed in liver 
samples of patients with hepatocellular carcinoma (HCC). Here we report on the functional characterization of 
DLC2. DLC2 protein contains three domains, which are sterile α motif (SAM), Rho GTPase-activating protein 
domain (GAP) and steroidogenic acute regulatory protein-related lipid transfer domain (START). Database 
searching and RT-PCR analyses revealed that there are four isoforms of DLC2, namely α, β, γ and δ. In vitro and in 
vivo studies confirmed that the GAP and START domains in DLC2 are functional. In vitro GAP assay indicated 
that DLC2 GAP preferentially activated hydrolysis of GTP in both Rho and Cdc42 GTPases, but not Rac GTPase. 
Overexpression of DLC2 in HeLa and Huh-7 cell lines induced the depolymerization of stress fiber, leading to 
morphological changes and remodeling of actin cytoskeleton. Deletion studies demonstrated that the GAP domain 
alone is responsible for actin depolymerization, and neither SAM nor START was involved in that process, 
although those two domains might attenuate the function of GAP. For the study of START domain, we 
overexpressed either a myc-tagged or V5-tagged form of DLC2 START domain in Huh-7 hepatoma cells. Those 
two mutants were dispersedly distributed to peculiar subcellular compartments around lipid droplets in the cytosol. 
We also assessed the involvement of DLC2 START domain in the lipid transport/efflux in hepatoma cells, and we 
found that either full-length DLC2 or truncated DLC2 mutant with the START domain could only up-regulate the 
expression of ATP-binding cassette transporter ABCA1, an important mediator of phospholipid and cholesterol 
efflux. Taken together, our findings suggest that DLC2 can remodel cell morphology through its GAP domain and 
modulate cellular lipid transfer through its START domain. 
